Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mast Cell-Derived SAMD14 Is a Novel Regulator of the Human Prostate Tumor Microenvironment.
Teng LKH, Pereira BA, Keerthikumar S, Huang C, Niranjan B, Lee SN, Richards M, Schittenhelm RB, Furic L, Goode DL, Lawrence MG, Taylor RA, Ellem SJ, Risbridger GP, Lister NL. Teng LKH, et al. Among authors: furic l. Cancers (Basel). 2021 Mar 11;13(6):1237. doi: 10.3390/cancers13061237. Cancers (Basel). 2021. PMID: 33799802 Free PMC article.
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer.
Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomery MK, Papargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, Nomura DK, Taylor RA. Watt MJ, et al. Among authors: furic l. Sci Transl Med. 2019 Feb 6;11(478):eaau5758. doi: 10.1126/scitranslmed.aau5758. Sci Transl Med. 2019. PMID: 30728288
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, Pook D, Pezaro CJ, Sandhu S, Keerthikumar S, Quezada Urban R, Papargiris M, Kraska J, Madsen HB, Wang H, Richards MG, Niranjan B, O'Dea S, Teng L, Wheelahan W, Li Z, Choo N, Ouyang JF, Thorne H, Devereux L, Hicks RJ, Sengupta S, Harewood L, Iddawala M, Azad AA, Goad J, Grummet J, Kourambas J, Kwan EM, Moon D, Murphy DG, Pedersen J, Clouston D, Norden S, Ryan A, Furic L, Goode DL, Frydenberg M, Lawrence MG, Taylor RA. Risbridger GP, et al. Among authors: furic l. Nat Commun. 2021 Aug 19;12(1):5049. doi: 10.1038/s41467-021-25175-5. Nat Commun. 2021. PMID: 34413304 Free PMC article.
Pro-tumorigenic role of ERα in prostate cancer cells.
Furic L, Lawrence MG, Risbridger GP. Furic L, et al. Aging (Albany NY). 2015 Jun;7(6):356-7. doi: 10.18632/aging.100769. Aging (Albany NY). 2015. PMID: 26143334 Free PMC article. No abstract available.
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP. Lawrence MG, et al. Among authors: furic l. Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23. Eur Urol. 2018. PMID: 30049486 Free PMC article.
CRISP3 expression drives prostate cancer invasion and progression.
Volpert M, Furic L, Hu J, O'Connor AE, Rebello RJ, Keerthikumar S, Evans J, Merriner DJ, Pedersen J, Risbridger GP, McIntyre P, O'Bryan MK. Volpert M, et al. Among authors: furic l. Endocr Relat Cancer. 2020 Jul;27(7):415-430. doi: 10.1530/ERC-20-0092. Endocr Relat Cancer. 2020. PMID: 32357309
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.
Lawrence MG, Porter LH, Choo N, Pook D, Grummet JP, Pezaro CJ, Sandhu S, Ramm S, Luu J, Bakshi A, Goode DL, Sanij E, Pearson RB, Hannan RD, Simpson KJ, Taylor RA, Risbridger GP, Furic L. Lawrence MG, et al. Among authors: furic l. Mol Cancer Ther. 2021 Nov;20(11):2140-2150. doi: 10.1158/1535-7163.MCT-20-0932. Epub 2021 Aug 19. Mol Cancer Ther. 2021. PMID: 34413130
49 results